Gastrointestinal Infections

Dr. Thomas Sandora shares recent data on screening for asymptomatic carriage of Clostridium difficile and provides insight into what the preferred first-line treatment for the infection in children.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

One dose of microbiota-based therapy proved more effective than 2 at wiping out recurrent C. difficile infection.

Given the impressive efficacy of fecal microbiota transplantation (FMT) on decreasing recurrence of Clostridium difficile infection (CDI), the next logical step is seeing how it works for hospitalized patients with CDI.

SMUCLA implements high-touch wipe down intervention to address the need for environmental disinfection of cancer patient care areas.

Dr. Richard Vickers, discusses C. difficile rates in the United Kingdom.

Investigators develop a statistical model predicting which bacterial strains will engraft after FMT.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Fecal transplantation and molecular testing are among the new recommendations.

Dr. Richard Vickers, discusses what the next steps are for Summit Therapeutic’s ridinilazole.

Following an outbreak of norovirus in Pyeongchang ahead of the Winter Olympics, health officials are taking steps to stem the outbreak and keep attendees healthy.

Edmond Hooker, MD, DrPH, stresses that the FDA and the CDC need to intervene to ensure that hospital mattresses get cleaned appropriately.

Barley Chironda, RPN, CIC, stresses that understanding what motivates health care workers’ actions is crucial for reducing C. diff rates in hospitals.

Glenn Tillotson, PhD, FIDSA, explains how costs associated with Clostridium difficile compare with other problematic health care-associated infections.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The FDA grants 510(k) clearance to TECHLAB to market 2 noninvasive tests intended to aid in the diagnosis of campylobacteriosis.

Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.

Edmond Hooker, MD, DrPH, discusses a study that assessed the use of mattress covers in hospitals to cut down on CDI rates.

The FDA has approved Firvanq for the treatment of C. diff-associated diarrhea and enterocolitis caused by Staphylococcus aureus.

Dr. Richard Vickers, explains how ridinilazole affected the gut microbiome in participants of a phase 2 study.

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention.

Edmond Hooker, MD, DrPH, discusses how contaminated hospital mattresses act as a vector for spreading drug-resistant infections.

Dr. Richard Vickers, discusses how ridinilazole showed superior efficacy for the treatment of C. diff when compared with vancomycin in a phase 2 study.

Richard Haupt, MD, MPH, discusses what is needed to ensure that a future C. diff vaccine is adequately stocked and delivered to wherever individuals show up for vaccination.

SHEA has released expert guidance advising hospitals on when they can safely take patients with multidrug-resistant bacteria off of contact precautions.